Cancer Immunol Res. 2025 Mar 14:OF1-OF2. doi: 10.1158/2326-6066.CIR-25-0202. Online ahead of print.
ABSTRACT
Biomarkers of responsiveness to immune checkpoint blockade (ICB) are heavily sought given the breadth and depth of the use of ICB in cancer. PD-L1 expression was among the first biomarkers identified, but multiple factors have precluded more widespread use. In this issue, Galsky and colleagues utilize two separate PD-L1 assays to study urothelial carcinoma specimens and observe that SP142 (relative to 22C3) preferentially stains dendritic cells. These observations may help reconcile the discordant performance of the two PD-L1 assays in ICB-treated urothelial carcinoma while underscoring the role of dendritic cells in orchestrating ICB response. See related article by Galsky et al., p. XX .
PMID:40084809 | DOI:10.1158/2326-6066.CIR-25-0202